Follow US:
Over the past few years, biochemist John Jefferson Perry at the University of California, Riverside, has collaborated on a number of projects with Atomwise Inc., a company that uses artificial intelligence, or AI, for drug discovery. Now Perry and the company have formed a joint venture called Theia Biosciences. Perry’s...
UC Riverside mouse study provides insights into how pathological fear memory in PTSD could be suppressed
UC Riverside School of Medicine to lead engagement project in eastern Coachella Valley
UC Riverside-led study could inform the design of engineered nano-shells used in drug delivery
UC Riverside will lead collaborative effort at developing scalable quantum computers
UC Riverside-led rat study finds an immune receptor in the hippocampus is responsible for the onset of the disease after brain injuries
Zinc excess in the body correlates with oxidative stress
XMM-2599 lived fast and died young, says UC Riverside-led international team
Brandon Brown is an associate professor in the School of Medicine at UC Riverside
UC Riverside-led research has applications in ultrafast and spin-based nanoscale devices
NIH grant of $2.2 million could help researchers target two oncogenes, potentially leading to therapies for melanoma, lung cancer, and other tumors
Additional ongoing funding would help the medical school expand enrollment
UC Riverside research is supported by a four-year grant worth more than $1.2 million
UC Riverside research used internet data mining to monitor health effects reported by electronic cigarette users over time
UC Riverside physics students design a table-top experiment for the classroom
Calculations by UC Riverside’s Allen Mills predict metastable positronium bubbles in liquid helium
UC Riverside-led study is the first to show how tofacitinib affects epithelial cells lining the gut
UC Riverside-led study tested the effects of microgravity on intestinal epithelial cells
UC Riverside mouse study finds early exposure to sounds can address hypersensitivity to noise associated with Fragile X Syndrome
UC Riverside-led study could lead to the development of drugs that target liver and other cancers
